Moxier 400 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Moxifloxacin hydrochloride tablet |
| Company | Euro pharma ltd |
Indications
Moxier is indicated for the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community acquired pneumonia, uncomplicated & complicated skin and skin structure infections, complicated intra-abdominal infections and pelvic inflammatory disease.
Pharmacology
Moxifloxacin is a 4th generation synthetic broad spectrum, fluoroquinolone class of antibacterial drug. It acts by inhibiting topoisomerase II (DNA gyrase) and topoisomerase IV which are necessary for bacterial DNA replication, transcription & repair.
Dosage & Administration
- 400 mg once daily for 7-10 days for acute bacterial sinusitis
- 400 mg once daily for 5-10 days for acute bacterial exacerbation of chronic bronchitis
- 400 mg once daily for 7-14 days for community-acquired pneumonia
- 400 mg once daily for 7 days for uncomplicated skin and skin structure infections
- 400 mg once daily for 7-21 days for complicated skin and skin structure infections
- 400 mg once daily for 5-14 days for complicated intra-abdominal infections
- 400 mg once daily for 14 days for pelvic inflammatory disease
Interaction
Moxier absorption is decreased when administered with antacids, sucralfate, multivitamins, and multivalent cations (e.g. iron or zinc). Moxier may enhance the risk of convulsions with NSAIDs and bleeding with warfarin.
Contraindications
It is contraindicated in patients with a history of hypersensitivity to Moxifloxacin or other quinolones.
Side Effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Dizziness
Pregnancy & Lactation
Moxifloxacin is not recommended during pregnancy & lactation.
Precautions & Warnings
Moxier may cause an increased risk of tendinitis and tendon rupture. It should not be used in patients with known prolongation of the QT interval, uncorrected hypokalemia, and receiving Class IA or Class III antiarrhythmic agents
Use in Special Populations
- No dose adjustment is necessary for patients with renal or hepatic impairment
- Safety and effectiveness of Moxier in pediatric patients and adolescent less than 18 years of age have not been established.
Therapeutic Class
4-Quinolone preparations
Storage Conditions
Keep in a dry place, away from light and heat. Keep out of the reach of children.